Pre clinical biotechnology company: Spyre Therapeutics, Inc. (SYRE)

Spyre Therapeutics, Inc. (NASDAQ: SYRE) was founded in 2013. The company's original name was Aeglea BioTherapeutics, Inc., which was changed to its current name in November 2023. Headquartered in Waltham, Massachusetts, Spyre Therapeutics, Inc. is a pre clinical company with 30 full-time employees Biotechnology Company , focusing on developing treatment methods for patients with inflammatory bowel disease (IBD).

The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/syre.html

Spyre Therapeutics, Inc. (SYRE)

Spyre Therapeutics focuses on developing next-generation therapies for IBD patients, including ulcerative colitis (UC) and Crohn's disease (CD). Spyre's new proprietary monoclonal antibody candidate product portfolio has the potential to address unmet needs in IBD care. If approved, Spyre believes that its candidate products may provide promising treatment options to help patients with IBD. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/syre.html

Spyre Therapeutics developed SPY001, a human monoclonal immunoglobulin G1 antibody, which is designed to selectively bind to a4 ß 7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/syre.html

Spyre Therapeutics is also developing SPY002, a human monoclonal antibody (mAb) candidate drug designed to bind to tumor necrosis factor like ligand 1A; SPY120 is a combination of SPY001 (anti a4 ß 7) and SPY002 (anti TL1A) antibodies, which is currently in the pre clinical research stage. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/syre.html

In addition, other early projects of Spyre Therapeutics include SPY003, a monoclonal antibody against IL-23; SPY004, a new mechanism of action (MOA) monoclonal antibody; SPY130, combination of anti-a4 ß 7 and anti-IL-23 mAb; SPY230, a combination of anti TL1A and anti IL-23 mAb. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/syre.html

On November 27, 2023, biotechnology companies in the development stage Aeglea BioTherapeutics, Inc. (NASDAQ stock code: AGLE) announced that it was renamed Spyre Therapeutics, Inc. From the opening on November 28, 2023, Spyre will be traded on NASDAQ with the stock code of "SYRE". This renaming was carried out after the company acquired the privately held Spyre Therapeutics, Inc. in June 2023. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/syre.html

Spyre Therapeutics, Inc. (SYRE) US equity investment